ALK and lymphoma: Cell sensitivity to the peptide was dependent on ALK expression by tumor cells as: (i) ALK-negative tumor cells failed to respond and (ii) expressing either NPM–ALK or full-length ALK restored P36-responsiveness of lymphoma or neuroblastoma cells, respectively.